Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 2006 Homer W. Smith Lecture: taming T cells.

Literature DB >> 17942948

2006 Homer W. Smith Lecture: taming T cells.

Terry B Strom¹.

Abstract

Mesh：

Substances：
Interleukin-2

Year: 2007 PMID： 17942948 PMCID： PMC3747559 DOI： 10.1681/ASN.2007070832

Source DB: PubMed Journal: J Am Soc Nephrol ISSN： 1046-6673 Impact factor: 10.121

× No keyword cloud information.

68 in total

1. Anti-interleukin 2 receptor antibody suppresses delayed-type hypersensitivity to foreign and syngeneic antigens.

Authors: V E Kelley; D Naor; N Tarcic; G N Gaulton; T B Strom
Journal: J Immunol Date: 1986-10-01 Impact factor: 5.422

2. The early (18-hr) human mixed lymphocyte reaction: identification and isolation of activated T-cell clones.

Authors: A A Ythier; J M Williams; H M Shapiro; V E Kelley; T B Strom
Journal: Cell Immunol Date: 1985-03 Impact factor: 4.868

3. Heightened intragraft CTL gene expression in acutely rejecting renal allografts.

Authors: M L Lipman; A C Stevens; T B Strom
Journal: J Immunol Date: 1994-05-15 Impact factor: 5.422

4. Cellular components of allograft rejection: identity, specificity, and cytotoxic function of cells infiltrating acutely rejecting allografts.

Authors: T B Strom; N L Tilney; J M Paradysz; J Bancewicz; C B Carpenter
Journal: J Immunol Date: 1977-06 Impact factor: 5.422

5. Rapamycin treatment depresses intragraft expression of KC/MIP-2, granzyme B, and IFN-gamma in rat recipients of cardiac allografts.

Authors: K J Wieder; W W Hancock; G Schmidbauer; C L Corpier; I Wieder; L Kobzik; T B Strom; J W Kupiec-Weglinski
Journal: J Immunol Date: 1993-07-15 Impact factor: 5.422

6. Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats.

Authors: J W Kupiec-Weglinski; T Diamantstein; N L Tilney; T B Strom
Journal: Proc Natl Acad Sci U S A Date: 1986-04 Impact factor: 11.205

7. Characterization of a monoclonal rat anti-mouse interleukin 2 (IL-2) receptor antibody and its use in the biochemical characterization of the murine IL-2 receptor.

Authors: G N Gaulton; J Bangs; S Maddock; T Springer; D D Eardley; T B Strom
Journal: Clin Immunol Immunopathol Date: 1985-07

8. Quantitative comparison of rapamycin and cyclosporine effects on cytokine gene expression studied by reverse transcriptase-competitive polymerase chain reaction.

Authors: X X Zheng; T B Strom; A W Steele
Journal: Transplantation Date: 1994-07-15 Impact factor: 4.939

2006 Homer W. Smith Lecture: taming T cells.

1. Anti-interleukin 2 receptor antibody suppresses delayed-type hypersensitivity to foreign and syngeneic antigens.

2. The early (18-hr) human mixed lymphocyte reaction: identification and isolation of activated T-cell clones.

3. Heightened intragraft CTL gene expression in acutely rejecting renal allografts.

4. Cellular components of allograft rejection: identity, specificity, and cytotoxic function of cells infiltrating acutely rejecting allografts.

5. Rapamycin treatment depresses intragraft expression of KC/MIP-2, granzyme B, and IFN-gamma in rat recipients of cardiac allografts.

6. Therapy with monoclonal antibody to interleukin 2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats.

7. Characterization of a monoclonal rat anti-mouse interleukin 2 (IL-2) receptor antibody and its use in the biochemical characterization of the murine IL-2 receptor.

8. Quantitative comparison of rapamycin and cyclosporine effects on cytokine gene expression studied by reverse transcriptase-competitive polymerase chain reaction.

9. The effect of anti-interleukin-2 receptor monoclonal antibody on allograft rejection.

10. Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice.

Review 1. Strategies to modulate immune responses: a new frontier for gene therapy.

Review 2. Pharmacologic targeting of regulatory T cells for solid organ transplantation: current and future prospects.

3. Creating transplant tolerance by taming adverse intragraft innate immunity.